Brought to you by 
CoCensys swaps Acea 1021 to Ciba for marketed CNS drugs
24 Oct 2019
Executive Summary
Ciba has licensed CoCensys' CNS drug, Acea 1021 (acquired from Acea Pharmaceuticals in 10/92), in exchange for equity purchases, milestones, royalties, R&D payments, and co-promotion rights to three of Ciba's currently-marketed psychiatric drugs.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CoCensys swaps Acea 1021 to Ciba for marketed CNS drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice